Organization (Industry)
Zenas BioPharma, Inc.
ClinicalTrials.gov lists Zenas BioPharma, Inc. as lead sponsor of 10 trials. It has 9 active development programs.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 2 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Zenas BioPharma, Inc.: 10 lead-sponsored trials and 1 legal-entity registration.
Disease areas (8)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Multiple Sclerosis | 3 |
| Multiple Sclerosis, Chronic Progressive | 2 |
| Arthritis, Rheumatoid | 1 |
| Graves Disease | 1 |
| Graves Ophthalmopathy | 1 |
Showing 5 of 8 disease areas.
Trials by start year as sponsor or collaborator (4)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2024 | 2 |
| 2023 | 4 |
| 2022 | 2 |
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (9)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Orelabrutinib | Multiple Sclerosis | Phase 3 | 2 |
| Orelabrutinib | Multiple Sclerosis, Chronic Progressive | Phase 3 | 2 |
| Obexelimab | Immunoglobulin G4-Related Disease | Phase 3 | 1 |
| Obexelimab | Lupus Erythematosus, Systemic | Phase 2 | 1 |
| Obexelimab | Multiple Sclerosis | Phase 2 | 1 |
Showing 5 of 9 active programs.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 67% hit target (n=6) | 50% on time (n=6) |
SEC-reported annual financials (4)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 10,000,000 | -377,737,000 | 168,063,000 |
| 2024 | 5,000,000 | -156,988,000 | 139,139,000 |
| 2023 | 50,000,000 | -37,124,000 | 60,033,000 |
| 2022 | not reported | not reported | not reported |
Financing and grant events (18)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-03-31 | Debt financing | 193,700,000 | Sec extracted |
| 2026-03-31 | Public offering | 93,700,000 | Sec extracted |
| 2026-03-30 | Follow-on offering | 115,000,000 | Edgar offerings |
| 2026-03-30 | Follow-on offering | 230,000,000 | Edgar offerings |
| 2026-03-26 | Other financing | not disclosed | Edgar offerings |
Showing 5 of 18 events.
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Latest dated events (29)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026 Q2 | PDUFA decision date | Regulatory decision dates extracted from SEC filings |
| 2026-03-31 | Public offering | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-03-31 | Debt facility | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-03-30 | Follow-on offering | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-03-30 | Follow-on offering | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 29 events.
Biomarker capability evidence (22)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| BCAR1 | Trial sponsor | Named in trial inclusion criteria |
| CSE1L | Trial sponsor | Named in trial inclusion criteria |
| OPN1LW | Trial sponsor | Primary endpoint in a Phase 3 trial |
| RAB11FIP1 | Trial sponsor | Primary endpoint in a Phase 3 trial |
| RD3 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 22 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, approved assets, journals published in, us granted patents, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.